Chronic myelocytic leukemia as a second neoplasia in the course of chronic lymphocytic leukemia—Case report and review of the literature

Teichmann, J. V.; Sieber, G.; Ludwig, Wolf‐Dieter; Karow, J.; Ruehl, H.

doi:10.1016/0145-2126(86)90064-0

Cited by 21 publications

(18 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similar observations have been made in patients with CLL [109]. Possible explanations were immunological deficiencies due to the disease, therapy-induced immunosuppression, and the prolonged survival of patients as a result of improved therapeutic options or genetic predisposition [98,109]. A recent report reviewed second(ary) malignancies in 117 patients with HCL [7]; 36 patients developed a second neoplastic disease prior to (np12), concurrent with (np3), or after (np21) the ID of HCL, with a peak within 2 years after diagnosis.…”

Section: Preclinical Phase Of CMLsupporting

confidence: 78%

Section: Preclinical Phase Of CMLsupporting

confidence: 54%

“…A higher frequency of melanomatous and nonmelanomatous skin cancer, as well as of lung cancer and adenocarcinoma of the GI tract, has also been described [7]. Although the majority of patients with CLL who developed CML had received either RT or alkylating agents (chlorambucil) (np8) [4,26,62,78,102,109,123,124], four cases of secondary CML in untreated patients have also been reported (Table 2) [45,92,123,124]. The median interval to development of CML was 30 months (range 17-53 months), which is similar to that reported in a recent study on HCL patients treated for their disease, with a peak incidence of secondary malignancies within the first 2 years after ID of HCL [7].…”

Section: Preclinical Phase Of CMLmentioning

confidence: 99%

See 2 more Smart Citations

Treatment-related chronic myelogenous leukemia

Waller

Fetscher

Lange

1999

Annals of Hematology

View full text Add to dashboard Cite

Treatment-related (Tr) AML and MDS after chemotherapy, radiotherapy, or the combination of both have been well characterized. However, tr-CML seems to differ from these better-known entities in frequency, clinical course, and prognosis. Tr-CML cannot be distinguished from de novo CML cytogenetically, and, in contrast to tr-AML and tr-MDS, typical chromosomal aberrations related to tr-CML have not been described. Treatment-related CML is a late effect of cytotoxic or immunosuppressive therapy which might be increasingly recognized due to a higher number of patients treated with intensive therapy regimens. We review here the available data on incidence of tr-CML as well as the affected individual's characteristics with regard to different treatment options in malignant and nonmalignant diseases.

show abstract

Section: Preclinical Phase Of CMLsupporting

confidence: 78%

Section: Preclinical Phase Of CMLsupporting

confidence: 54%

Section: Preclinical Phase Of CMLmentioning

confidence: 99%

See 1 more Smart Citation

Treatment-related chronic myelogenous leukemia

Waller

Fetscher

Lange

1999

Annals of Hematology

View full text Add to dashboard Cite

show abstract

“…There are few reports of secondary CML following chemotherapy; we identified sixteen [1,4,9,11,13,16,19,24,27,29,34,35,37,38]. These cases are summarized in Table 2.…”

Section: Discussionmentioning

confidence: 92%

A case of chronic myeloid leukemia with minor bcr-abl transcript following fluorouracil therapy for esophageal carcinoma

Nakamura

Inokuchi

Hanawa

et al. 2000

Annals of Hematology

View full text Add to dashboard Cite

We report here a very rare case of chronic myeloid leukemia (CML) with a minor bcr-abl transcript, which developed following long-term chemotherapy with fluorouracil for esophageal carcinoma. A 64-year-old male patient was diagnosed with CML. Four years earlier, he had suffered from esophageal carcinoma, which was treated by surgical resection followed by oral administration of fluorouracil (200 mg/day) for 4 years. Molecular analysis of his Philadelphia chromosome (Ph) using reverse-transcriptase polymerase chain reaction (RT-PCR) and subsequent sequencing revealed a minor bcr-abl transcript. The clinical course of this patient was aggressive with a short chronic phase of CML. This is the first reported case of secondary CML with a minor bcr-abl transcript.

show abstract

“…In fact, the role of impairment of the immune system was confirmedbythedevelopmentofCMLfollowingrenaltransplantationinpatientsreceivingazathioprinewithorwithout prednisone [20] as well as by the high incidence of second malignancies due to immunological deficiencies in hairy cell leukemia [21]andchroniclymphocyticleukemia [22].Inour case, CML development could be related to immunological alterations associated with DLBCL. Indeed, in a recent report,theauthorsdemonstratedthatNHLinpediatricpatients was associated with elevated levels of inflammatory and immune-regulating cytokines [23].…”

Section: Discussionmentioning

confidence: 93%

Chronic Myeloid Leukemia as a Secondary Malignancy after Lymphoma in a Child. A Case Report and Review of the Literature

Zahra

Fredj²,

Youssef³

et al. 2012

Onkologie

View full text Add to dashboard Cite

Background: Philadelphia chromosome-positive chronic myeloid leukemia (CML) in children is very rare. CML occurring as a secondary malignancy in individuals treated for diffuse large B-cell lymphoma (DLBCL) is also rare. Case Report: We present the case of a 5-year-old female patient who developed a right orbital mass that was diagnosed as DLBCL. 9 months after receiving treatment for DLBCL, she presented with a white cell count of 250,000/mm³. Peripheral blood and bone marrow (BM) evaluation revealed a myeloproliferative disorder. Cytogenetic and molecular studies demonstrated the presence of t(9;22). CML following DLBCL has not been previously described in the younger population. To our knowledge, this is the first report of a child who developed a CML as a second malignancy after DLBCL. Therapy-related CML and non-therapy-related secondary CML are discussed as potential explanations of this highly unusual clinical presentation. Conclusion: Hematological disorders such as CML may occur after lymphomas. With the increased use of BM cytogenetic studies during staging for lymphoid malignancies, future studies may be able to clarify the question of whether the CML clone in some of these patients existed before treatment for lymphoma.

show abstract

Chronic myelocytic leukemia as a second neoplasia in the course of chronic lymphocytic leukemia—Case report and review of the literature

Cited by 21 publications

References 34 publications

Treatment-related chronic myelogenous leukemia

Treatment-related chronic myelogenous leukemia

A case of chronic myeloid leukemia with minor bcr-abl transcript following fluorouracil therapy for esophageal carcinoma

Chronic Myeloid Leukemia as a Secondary Malignancy after Lymphoma in a Child. A Case Report and Review of the Literature

Contact Info

Product

Resources

About